NEW YORK, Jan. 13, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has reached the midway point in a continuing pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain. The midway point in the dosing study has been reached with no evidence of dose-limiting toxicity.
Racemic methadone is a long-acting opioid used in the treatment of various pain states and as a substitution therapy in opioid addiction. It is constituted by a 50/50 combination of two isomers: an l-isomer that is a potent opioid agonist, and a d-isomer that has virtually no opioid activity at the proposed doses and that has also been shown to possess NMDA antagonist properties. The activation of NMDA receptors has been associated with neuropathic pain and d-Methadone may have a role in pain management by blocking this activity.
"We are pleased to have reached the midway point in this Phase I clinical trial evaluating the safety and tolerability of d-Methadone," stated Sergio Traversa, chief executive officer of Relmada Therapeutics. "The data generated in this trial will help guide our determination of the appropriate dosing in our planned later stage clinical trials for the treatment of a range of neuropathic pain conditions, which continues to represent a significant unmet need and commercial opportunity in healthcare."
Relmada is planning two initial studies designed to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of d-Methadone in healthy subjects. The ongoing study is investigating single escalating oral doses of d-Methadone. In the planned second study, healthy subjects will receive multiple daily oral doses of d-Methadone. The data from these studies will inform the design of a subsequent Phase 2 proof of concept study in neuropathic pain.
About Neuropathic Pain
Neuropathic pain is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The term neuropathic pain is used to describe a wide range of pain syndromes, including painful diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. According to the Neuropathy Association, neuropathic pain is estimated to affect more than 20 million people in the United States alone. The main classes of drugs used to treat these neuropathic pain conditions are anticonvulsants, antidepressants, opioids, and topical treatments. However, despite the availability of multiple pain medications only about 50% of patients respond to treatment with currently available therapy options, and they present the risk of numerous side effects that reduce their tolerability.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.
This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Berry & Company Public Relations
SOURCE Relmada Therapeutics, Inc.